Tremor-predominant Parkinson's disease. Approaches to treatment

Drugs and Aging

Volumn 16, Issue 4, 2000, Pages 273-278

  Marjama Lyons, Jill ^a   Koller, William ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LEVODOPA; PROPRANOLOL;

ARTICLE; BODY POSTURE; BRADYKINESIA; BRAIN DEPTH STIMULATION; DISABILITY; GLOBUS PALLIDUS; MUSCLE RIGIDITY; NEUROSURGERY; PARKINSON DISEASE; PRIORITY JOURNAL; SUBTHALAMIC NUCLEUS; THALAMUS; THERMOCOAGULATION; TREMOR;

EID: 0034074681     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016040-00003     Document Type: Article

References (46)

1. 1. Martin WE, Lowenson RB, Resch JA, et al. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 1974; 24: 912-9
2. 2. Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neural 1986; 43: 126-7
3. 3. Young RR, Shahani BT. Pharmacology of tremor. Clin Neuropharm 1979; 4: 139-56
4. 4. Deuschl G, Lucking CH. Tremor and electrically elicited long-latency reflexes in early stages of Parkinson's disease. In: Riederer HP, editor. Early diagnosis and preventive therapy of Parkinson's disease. New York: Springer Verlag, 1989: 103-10
5. 5. Laihinen A, Rinne UK, Suchy I. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease. Acta Neurol Scand 1992; 86: 593-5
6. 6. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995; 45: 513-21
7. 7. Pahwa R, Koller WC. Dopamine agonists in the treatment of Parkinson's disease. Cleve Clin J Med 1995; 62: 212-7
8. 8. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. Mov Disord 1994; 9: 431-6
9. 9. Pezzoli G, Martignoni E, Pacchetti C, et al. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 1995; 45: S22-7
10. 10. Corbin KB. Trihexyphenidyl: evaluation of the new agent in the treatment of parkinsonism. JAMA 1949; 141: 377-82
11. 11. Cantello R, Riccio A, Gilli M, et al. Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients. Ital J Neurol Sci 1986; 7: 139-43
12. 12. Piccirilli M, D'Alessandro P, Testa A, et al. Bornaprine in the treatment of Parkinsonian tremor. Riv Neurol 1985; 55: 38-45
13. 13. Bonuccelli U, Ceravolo R, Salvetti S, et al. Clozapine in Parkinson's disease tremor: effects of acute and chronic administration. Neurology 1997; 49: 1587-90
14. 14. Jansen EN. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994; 89: 262-5
15. 15. Freidman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5: 225-9
16. 16. Stromberg V, Svensson TH. Furher studies on the mode of action of amantadine. Acta Pharmacol Toxicol 1971; 30: 161-71
17. 17. Von Voigtlander PF, Moore KE. Dopamine release from the brain in vivo by amantadine. Science 1971; 174: 408-10
18. 18. Fahn S, Isgreen W. Long term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses. Neurology 1985; 25: 695-700
19. 19. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. Neurology 1975; 25: 603-6
20. 20. Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology 1987; 37: 471-4
21. 21. Loeb C, Priano A. Preliminary evaluation of the effects of clonazepam on parkinsonian tremor. Eur Neurol 1977; 15: 143-5
22. 22. Koller WC, Herbster G. Adjuvant therapy of parkinsonian tremor. Arch Neurol 1987; 44: 921-3
23. 23. Foster NL, Newman RP, LeWitt PA, et al. Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Ann Neurol 1984; 16: 505-8
24. 24. Findley LJ, Cleeves L, Calzetti S. Long-term use of propranolol in essential tremor. In: Marsden CD, Benecke R, editors. Motor disorders I. London: Academic Press, 1986: 232-41
25. 25. Yoshii F, Shinohara Y, Takeoka T, et al. Treatment of essential and parkinsonian tremor with Nipradilol. Intern Med 1996; 35: 861-5
26. 26. Olson WL, Gruenthal M, Mueller ME, et al. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med 1997; 102: 60-6
27. 27. Scoll AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalmol Soc 1981; 79: 734-70
28. 28. Jancovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 124: 1186-94
29. 29. Pullman SL, Greene P, Fahn S, et al. Approach to the treatment of limb disorders with botulinum toxin A: experience with 187 patients. Arch Neurol 1996; 53: 617-24
30. 30. Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Dis 1994; 9: 601-9
31. 31. Henderson JM, Ghika JA, Van Melle G, et al. Botulinum toxin A in non-dystonic tremors. Eur Neurol 1996; 36: 29-35
32. 32. Kelly PJ, Gillingham FJ. The long-term results of stereo-taxic surgery and L-dopa therapy in patients with Parkinson's disease: a 10-year follow-up study. J Neurosurg 1980; 53: 332-7
33. 33. Jankovic J, Cardoso F, Grossman RG, et al. Outcome after stereotactic thalamotomy for Parkinsonian, essential, and other types of tremor. Neurosurgery 1995; 45: 1743-46
34. 34. Tasker RR. Movement disorders. In: Apuzzo MLJ, editor. Brain surgery: complication avoidance and management. New York: Churchill Livingstone, 1993: 1509-24
35. 35. Vitek JL, Bakay RAE, Delong MR. Posteroventral pallidotomy for Parkinson's disease. In: Obeso JA, editor. The basal ganglia and surgical treatment of Parkinson's disease: advances in neurology. Vol 74. Philadelphia: Lippincott, 1997: 183-98
36. 36. Fazzini E, Dogali M, Sterio D, et al. Stereotactic pallidotomy for Parkinson's disease: a long-term follow-up of unilateral pallidotomy. Neurology 1997; 48: 1273-7
37. 37. Kishore A, Turnbull IM, Snow BJ, et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease: six month follow-up with additional one year observation. Brain 1997; 120: 729-38
38. 38. Lozano AM. Lang AE, Galvez-Jimenez N, et al. Effect of GPI pallidotomy on motor fuction in Parkinson's disease. Lancet 1995; 346: 1383-7
39. 39. Taha JM, Fauvre J, Baumann TK, et al. Tremor control after pallidotomy in patients with Parkinson's disease: correlation with microrecording findings. J Neurosurg 1997; 86: 642-7
40. 40. Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996; 84: 203-14
41. 41. Krack P, Benazzouz A, Pollak P. et al. Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. Mov Disord 1998; 13: 907-14
42. 42. Pahwa R, Wilkinson S, Smith D, et al. High frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. Neurology 1997; 49: 249-53
43. 43. Gross C, Rougier A, Guehl D, et al. High frequency stimulation of the Globus Pallidus internalis in Parkinson's disease: a study of seven cases. J Neursurg 1997; 87: 471-98
44. 44. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol 1998; 49: 145-53
45. 45. Young RF. Functional neurosurgery with the Leskell Gamma knife. Stereotact Funct Neurosurg 1996; 66: 19-23
46. 46. Duma CM, Jacques DB, Kopyov OV, et al. Gamma knife radio-surgery for thalamotomy in Parkinsonian tremor: a five-year experience. J Neurosurg 1998; 88: 1121-2